Why We Invested · Sapphire Ventures
Why the firm invested
Series C funding will be used to expand Medable's go-to-market and customer success teams.
This latest funding round will enable Medable to meet surging demand by staffing up go-to-market and customer success teams.
Product
Medable's platform reduces trial times, increases patient access, and improves patient experience.
Medable’s approach substantially reduces trial times, increases patient access and improves the patient experience, ultimately resulting in better trial outcomes.
Medable features a cloud-based, modular platform with enterprise data and operational capabilities.
Its modern, flexible and cloud-based platform features unique modular technology that maximizes the benefits of digital in individual studies.
Medable offers solutions for remote patient screening, TeleVisit, TeleConsent, and TeleCOA.
Medable includes solutions for remote patient screening and enrollment, telemedicine (TeleVisit), remote eConsent (TeleConsent), and remote electronic Clinical Outcome Assessments (TeleCOA), which powers real time remote patient monitoring to track and analyze trial progress in real-time.
Traction
Medable counts the majority of the world's 20 largest biopharma companies as customers.
Founded in 2015, Medable already counts the majority of the largest 20 biopharma companies in the world among its customers.
Business model
As a software vendor, Medable partners with top global CROs as customers and distribution partners.
As a pure-play software vendor, Medable also partners with top global CROs, which are both customers and key distribution partners into the biggest global biopharma companies.
Investment context
Sapphire Ventures led Medable's $91 million Series C funding round.
We’re excited to share today that Sapphire Ventures is leading Medable’s $91 million Series C funding round.
What founders can learn
- What actually moved the decision: Sapphire Ventures wrote that Series C funding will be used to expand Medable's go-to-market and customer success teams.
- The traction evidence that carried weight: Sapphire Ventures wrote that Medable counts the majority of the world's 20 largest biopharma companies as customers.
- How the model was assessed: Sapphire Ventures wrote that As a software vendor, Medable partners with top global CROs as customers and distribution partners.
Source and provenance
Why We Invested published by Sapphire Ventures on sapphireventures.com (first-party source). Read the original
